M. tuberculosis Detection via Specific Lipid Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Mycobacterium tuberculosis (TB) infection are inefficient, with sputum smear microscopy being time-consuming and insensitive, serological tests producing false positives due to cross-reactivity with BCG vaccine and environmental mycobacteria, and existing tests failing to distinguish between TB and non-tuberculous mycobacteria infections.
Innovation Solution
Identification and measurement of specific compounds such as 1-tuberculosinyladenosine, N6-tuberculosinyladenosine, and mycoloyl-tuberculosinyladenosine, which are uniquely expressed by pathogenic Mycobacterium tuberculosis, allowing for accurate detection of TB infection without false positives from BCG vaccination or environmental mycobacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If sputum smear microscopy is used to diagnose M. tuberculosis, then the test can detect active pulmonary tuberculosis, but the sensitivity is low and it requires at least 10,000 MTb bacilli/mL to be detected
Solution Approach 1:
The patent replaces the mechanical/optical microscopy system with a mass spectrometry-based detection system. The mass spectrometry system detects specific lipid molecules (trehalose dimycolate and phenolic glycolipide) produced by M. tuberculosis, eliminating the need for visual detection of bacilli and achieving detection at much lower bacterial concentrations.
Solution Approach 2:
The patent introduces specific lipid molecules (trehalose dimycolate and phenolic glycolipide) as intermediary markers that are produced by M. tuberculosis. These lipid intermediaries serve as detectable signals that indicate the presence of the bacteria, allowing indirect detection with high sensitivity without requiring direct observation of bacilli.
2Measurement precision
If serological tests use immunodominant antigens to detect immunoglobulin classes, then the tests can detect M. tuberculosis exposure, but they produce false positive results due to cross-reactivity with BCG vaccine and environmental mycobacteria
Solution Approach 1:
The patent applies local quality by selecting specific lipid molecules (trehalose dimycolate and phenolic glycolipide) that are locally produced by M. tuberculosis but not by BCG vaccine strains or environmental mycobacteria. This localized molecular specificity eliminates cross-reactivity issues while maintaining detection capability.
Solution Approach 2:
The patent changes the detection parameter from detecting immunoglobulin classes (which cross-react) to detecting specific lipid molecules produced only by pathogenic M. tuberculosis. This parameter change from protein-based to lipid-based detection resolves the false positive problem while maintaining sensitivity.
3Measurement precision
If culture methods are used to grow and subculture bacteria to reach minimal concentration for testing, then the test can achieve sufficient sensitivity, but the process takes over two weeks to complete
Solution Approach 1:
The patent extracts and detects specific lipid molecules (trehalose dimycolate and phenolic glycolipide) directly from clinical samples without requiring bacterial culture. This extraction approach eliminates the time-consuming growth and subculture steps while maintaining detection sensitivity by targeting specific molecular markers.
Solution Approach 2:
The patent performs preliminary identification of M. tuberculosis-specific lipid markers before clinical testing. This preliminary action allows direct detection of these markers in patient samples without needing to first culture the bacteria, thereby eliminating the two-week waiting period while maintaining diagnostic accuracy.
4Measurement precision
If PCR methods are used to detect bacterial DNA, then the detection sensitivity is improved, but the methods are expensive and difficult to use in resource limited settings
Solution Approach 1:
The patent employs a mass spectrometry platform that can be implemented as a relatively simple, cost-effective system compared to PCR equipment. The method uses disposable sample preparation steps and detection of specific lipid molecules, avoiding the need for complex molecular biology reagents and equipment required for PCR, making it suitable for resource-limited settings.
Data Source
AI summary
Embodiments of the invention relate to methods and systems for the detection of Mycobacterium tuberculosis. Mycobacterium tuberculosis kills more than one million people each year. To better understand why M. tuberculosis is virulent and to discover chemical markers of this pathogen, we compared its lipid profile to that of the attenuated but related mycobacterium, Mycobacterium bovis Bacille Calmette Guerin (BCG). This strategy identified previously unknown compounds that are specific to M. tuberculosis, e.g. 1-tuberculosinyladenosine, N6-tuberculosinyladenosine, and various tuberculosinyladenosines having mycolic acids, produced by the Rv3378c enzyme.